On August 26, Samsung Biologics (207940) announced a contract order.
**Overview of Samsung Biologics Contract Order**
– Contract for pharmaceutical contract manufacturing worth 88.43 billion KRW (1.94% of sales)
Samsung Biologics (207940) disclosed on the 26th that it has entered into a single sales and supply agreement regarding pharmaceutical contract manufacturing (voluntary disclosure). The contracting party is a European pharmaceutical company, and the contract amount is about 88.43 billion KRW, which is approximately 1.94% of the recent sales of Samsung Biologics, which amounts to 4.55 trillion KRW. The duration of this contract is from August 26, 2025, to December 31, 2031, lasting about 6 years and 4 months.
Meanwhile, it was reported that this contract order was signed on August 26, 2025.
Contract orders can have a direct impact on the company’s performance in the future, so it is essential to pay close attention to the size and duration of the contract. Particularly, if contract orders increase but stock prices do not move, it may be a point of interest for potential buyers.
Hankyung Robo News
This article was automatically generated in real-time by an article generation algorithm developed jointly by Korea Economic Daily and the AI finance company, Thinkpool.